-

Tempus Introduces AI-enabled Assistant, Tempus One, Into Lens Data Analytics Platform to Accelerate Research

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced the integration of its signature Tempus One technology into its Lens data analytics platform. The AI-enabled Tempus One technology will leverage advancements in generative AI to provide researchers the tools they need to seamlessly analyze Tempus’ de-identified, multimodal data library to glean insights, build patient cohorts, interrogate patient populations, and more.

Tempus One was broadly released to physicians at the 2023 ASCO® Annual Meeting, designed as an AI-enabled clinical assistant that allows rapid and easy queries through voice or typing, leveraging access to their patients’ full clinical and molecular profile, combined with all relevant guidelines for up-to-date standard of care insights. Now, this generative AI technology is being introduced to Tempus’ research collaborators within the Tempus Lens platform, to more seamlessly identify and analyze cohorts of interest, to quickly answer questions and develop deeper insights.

The integration of Tempus One into Lens will begin with the inclusion of user Q&A through an in-app chat assistant powered by large language models (LLMs) across the Lens platform, which will make the vast amounts of data more accessible for researchers through the enhanced support function. Users will be able to send questions directly to the chat, receive real time answers including citations and links to additional information, and provide feedback on chat response quality. The integration will also include a cohort building technology facilitated by LLMs, allowing users to more quickly size and find patient cohorts across a hundred clinical and molecular attributes within Tempus’ dataset.

“We are looking forward to expanding our Tempus One technology to our life sciences collaborators,” said Ryan Fukushima, Chief Operating Officer of Tempus. “The incorporation of our generative AI capabilities into Lens will improve the functionality of the platform for users, so they can more easily leverage our data and insights at their fingertips.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Erin Carron
Senior Director of Communications
communications@tempus.com

Tempus


Release Versions

Contacts

Erin Carron
Senior Director of Communications
communications@tempus.com

More News From Tempus

Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley Technology, Media, and Telecom Conference on Tuesday, March 3 in San Francisco. Eric Lefkofsky, Tempus Founder and CEO, will participate in a fireside chat at 9:15 AM PST. The live webcast may be accessed directly using the following link: https://event.webcasts.com/starthere.jsp?ei=1753938&tp_k...

Tempus Reports Fourth Quarter and Full Year 2025 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2025. Fourth quarter revenue of $367.2 million, up 83.0% year-over-year with 33.5% organic growth (excluding Ambry) Diagnostics revenue of $266.9 million in the fourth quarter, representing 121.6% growth year-over-year, driven by Oncology volume growth of 29% and Hered...

Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This next-generation model represents a significant improvement in identifying Homologous Recombination Deficiency (HRD), providing a more robust, functional assessment of tumor biology compared to traditional static DNA-based assays. Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model de...
Back to Newsroom